Dacomitinib (Vizimpro) Approved for EGFRm NSCLC Dacomitinib (Vizimpro) Approved for EGFRm NSCLC

Another targeted agent is now available for use in the first-line treatment of metastatic non-small cell lung cancer (NSCLC) that harbors EGFR mutations.FDA Approvals

Source: Medscape Medical News Headlines - September 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news